ArticleFrontiers in immunology2026
Stapokibart's clinical effectiveness in treating moderate-to-severe bullous pemphigoid in the elderly.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the elderly, for whom conventional systemic corticosteroids and immunosuppressants pose significant safety risks due to age-related comorbidities, leading to infections, osteoporosis, and metabolic disorders. While stapokibart, a novel IL-4Rα inhibitor, holds promise for type 2 inflammatory diseases, clinical evidence regarding its efficacy in BP is currently lacking. Therefore, this study aims to observe the clinical efficacy and long-term safety of stapokibart in the treatment of moderate-to-severe BP in the elderly. Methods: This single-center, retrospective, uncontrolled case series included 15 elderly patients with moderate-to-severe BP. In addition to conventional topical glucocorticoids or combined systemic therapy, patients received an initial dose of 600 mg stapokibart, followed by 300 mg every 2 weeks. Dosage adjustments were made based on patients' clinical responses after 16 weeks. The core treatment period was 24 weeks, with a subsequent post-treatment follow-up duration ranging from 4 to 34 weeks (mean 18.78 ± 11.54 weeks). The primary outcome was explicitly defined as the achievement of disease control at 4 weeks. Secondary outcomes included the BP disease area index (BPDAI), dermatology life quality index (DLQI), itch numerical rating scale (NRS), absolute eosinophil count (EO), anti-BP180 antibody levels, relapse rate, and safety profiles, which were assessed at baseline and weeks 2, 4, 8, 16, and 24. Results: The primary outcome of disease control was achieved in 100.00% (15/15) of the patients within 4 weeks, with a mean time to control of 10.18 ± 3.06 days. Secondary outcomes including BPDAI, DLQI, itch NRS scores, EOs, and anti-BP180 antibody levels were all significantly reduced at week 24 compared to baseline (all Conclusion: Stapokibart may serve as an effective and well-tolerated adjunctive option for alleviating skin lesions and pruritus in elderly patients with moderate-to-severe BP. However, given the small sample size and uncontrolled retrospective design, larger, prospective randomized controlled trials are required to definitively confirm its long-term efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.